Home Stocks XWEL XWELL Inc. (NASDAQ: XWEL) Healthcare · Diagnostics & Research
— —
Quote unavailable · The latest market session has not been published.
The Quantellect read. The borrow fee is 10.83%. Zero active firms cover the stock as of Nov 18, 2026; zero active firms with targets average $7.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Mixed valuation signals P/S 0.3× vs peer median 4.5×
XWEL price chart Price — · As of —
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open —
Previous close —
Day range —
52-week range —
Volume —
Average volume (30 calendar days) —
Market cap —
P/E (TTM) —
Forward P/E —
EPS (TTM) —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history XWEL · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score 5 /100 Poor
Latest available: Nov 13, 2026 · updates irregularly
Each axis is a 0 to 100 percentile rank among equities
Liquidity 6 Short 48 Squeeze 19 Trend 9 Momentum 12 Valuation 64 Stability 19 What each one means Liquidity 6
Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.
Short 48
Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.
Squeeze 19
Higher scores reflect a higher published Squeeze score within equity peers.
Trend 9
Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.
Momentum 12
Higher scores reflect stronger 63- and 126-session total returns within equity peers.
Valuation 64
Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.
Stability 19
Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.
How the Q Score works → How XWEL compares with its industry Against 44 other US-listed Diagnostics & Research stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Strongest pointsFive-year annualized sales growth was 28.4%, higher than 87% of 31 peers.Peer median 7.5% · As of Nov 17, 2026 Points of cautionTrailing-year net margin was -82.9%, with only 7% of 43 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026 Trailing-year return on equity was -361.4%, with only 8% of 40 peers reporting a lower value.Peer median 0.6% · As of Nov 17, 2026 Six-month return was -66.5%, with only 10% of 42 peers reporting a lower value.Peer median 41.9% · As of Nov 16, 2026 Valuation Mixed valuation signals
Metric XWEL Peer median
Price/sales 0.26× 4.50×
Lowest 10% Higher than 9% of 44 peers
Forward P/E 10.79× 26.77×
Lowest 10% Higher than 10% of 30 peers
Price/book 20.33× 3.38×
Higher than 84% of 43 peers
Profitability Profitability metrics are lower than most peers.
Metric XWEL Peer median
Growth Growth metrics are mixed versus peers.
Metric XWEL Peer median
Balance sheet Balance sheet metrics are lower than most peers.
Metric XWEL Peer median
Momentum Returns are lower than most peers.
Metric XWEL Peer median
1-year return −41.2% +10.8%
Higher than 19% of 42 peers
6-month return −66.5% +41.9%
Bottom 10% of peers Higher than 10% of 42 peers
3-month return −48.6% +4.7%
Higher than 19% of 42 peers
How to read this The dot marks where XWEL ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 44 other US-listed Diagnostics & Research stocks · fundamentals as of Nov 15, 2026 · prices as of Nov 16, 2026
Upcoming events — · Upcoming events not available
Analyst consensus No Coverage
0 Strong Buy
0 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 0 active firms as of Nov 18, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $7.00
Average $7.00
High $7.00
As of Nov 18, 2026 across 0 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −6.00 −4.00 −2.00 0.00 Q3 ’24 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q2 2026 — −$0.26 —
Q1 2026 — −$1.51 —
Annual 2025 — −$5.08 —
Q3 2025 — −$0.26 —
Q2 2025 — −$0.56 —
Q1 2025 — −$1.00 —
Annual 2024 — −$3.66 —
Q3 2024 — −$0.99 —
Smart-money activity In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Sep 11, 2024 Insider buy Wizenberg Gaelle Sandra Buy $2.0K Form 4 May 7, 2024 Insider buy Wizenberg Gaelle Sandra Buy $368 Form 4 Apr 26, 2024 Insider buy Wizenberg Gaelle Sandra Buy $183 Form 4 May 30, 2023 Insider buy WEINSTEIN ROBERT Buy $6.2K Form 4 May 26, 2023 Insider buy WEINSTEIN ROBERT Buy $6.3K Form 4 All smart-money activity →
News and press releases Year All 2026 Aug 5, 2026, 9:15 AM ET Jul 7, 2026, 9:15 AM ET All XWEL news → Company profile XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers COVID-19 and other medical testing to the traveling public, as well as airline, airport and concessionaire employees, and TSA and
CEO Mr. Ezra T. Ernst
Headquarters New York, NY, United States
Employees 175
IPO date Jan 5, 2018
Sector Healthcare
Industry Diagnostics & Research Q Score 5 /100 Poor
Latest available: Nov 13, 2026 · updates irregularly
Each axis is a 0 to 100 percentile rank among equities
Liquidity 6 Short 48 Squeeze 19 Trend 9 Momentum 12 Valuation 64 Stability 19 What each one means Liquidity 6
Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.
Short 48
Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.
Squeeze 19
Higher scores reflect a higher published Squeeze score within equity peers.
Trend 9
Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.
Momentum 12
Higher scores reflect stronger 63- and 126-session total returns within equity peers.
Valuation 64
Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.
Stability 19
Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.
How the Q Score works → Upcoming events — · Upcoming events not available
Analyst consensus No Coverage
0 Strong Buy
0 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 0 active firms as of Nov 18, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $7.00
Average $7.00
High $7.00
As of Nov 18, 2026 across 0 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −6.00 −4.00 −2.00 0.00 Q3 ’24 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q2 2026 — −$0.26 —
Q1 2026 — −$1.51 —
Annual 2025 — −$5.08 —
Q3 2025 — −$0.26 —
Q2 2025 — −$0.56 —
Q1 2025 — −$1.00 —
Annual 2024 — −$3.66 —
Q3 2024 — −$0.99 —
Company profile XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers COVID-19 and other medical testing to the traveling public, as well as airline, airport and concessionaire employees, and TSA and
CEO Mr. Ezra T. Ernst
Headquarters New York, NY, United States
Employees 175
IPO date Jan 5, 2018
Sector Healthcare
Industry Diagnostics & Research